Fig. 6
From: HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma
PF-04691502 works synergistically with palbociclib to inhibit iCCA growth, EMT and stemness in vitro.
CCK − 8 assay (A), colony formation assay(B), 3D sphere formation assay(C), and transwell assay(D) analysis of iCCA cells treated with a single agent (PF-04691502 or palbociclib), a combination of both compounds at a fixed ratio (1:1) or shRNA-induced silencing of HMGA1.
Analyzed data were from three independent experiments and shown as means ± SEM. Analysis for statistical significance was performed using Student’s t-test (n.s.,**, *** and **** represented not significant, P < 0.01, < 0.001and < 0.0001, respectively )